Avidity Biosciences Inc (RNA)

A significant event impacting Avidity Biosciences' stock was the announcement on October 26, 2025, that Novartis would acquire the company for $12 billion, valuing Avidity shareholders at $72 per share. Prior to this, the stock had shown positive momentum, increasing by 0.76% in the week leading up to October 24, 2025, and by 16.88% in the preceding month. Over the last year, Avidity Biosciences' stock increased by 53.85% as of October 24, 2025. Earnings reports have also influenced the stock, with Q2 2025 and Q1 2025 missing analysts' estimates, while Q4 2024 was in line with estimates, and Q3 2024 beat estimates.

As a clinical-stage biopharmaceutical company without commercial products generating sales revenue, the concept of demand seasonality is not applicable to Avidity Biosciences, Inc. The company's valuation and market interest are primarily driven by the progress of its clinical trials, regulatory milestones, and the potential of its proprietary technology.

Avidity Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing Antibody Oligonucleotide Conjugates (AOCs) to treat diseases previously considered untreatable with traditional RNA therapeutics. The company's primary focus is on rare muscle diseases, with product candidates in clinical development for Myotonic Dystrophy Type 1 (DM1), Facioscapulohumeral Muscular Dystrophy (FSHD), and Duchenne Muscular Dystrophy (DMD). Avidity is also expanding its research into precision cardiology and immunology through internal discovery and partnerships.

Avidity Biosciences, Inc. is headquartered in La Jolla, California, USA. Its global presence is established through clinical trial activities conducted in collaboration with international research institutions and investigators across various countries.

Avidity Biosciences has cultivated a positive brand reputation within the biotechnology sector, driven by its innovative approach to RNA therapeutics and promising clinical trial results. Positive initial data from the FORTITUDE™ trial and the recent acquisition by Novartis have further underscored Avidity's strategic importance and the perceived value of its technology and pipeline.

Avidity Biosciences, Inc. is a publicly traded company with ownership distributed among institutional investors, the general public, and company insiders. Approximately 41.31% of the company's stock is owned by Institutional Investors, 0.73% by Insiders, and 57.96% by Public Companies and Individual Investors. Major institutional owners include Fmr Llc, Price T Rowe Associates Inc /md/, Janus Henderson Group Plc, RTW Investments, Lp, BlackRock, Inc., Wellington Management Group Llp, Vanguard Group Inc, Ra Capital Management, L.p., Avoro Capital Advisors LLC and State Street Corp.